Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights

Figures & data

Table 1 Summary of the Position of Lenvatinib in Current International Guidelines

Guideline	Year	Recommendation	Ref.
NCCN	2023	Recommended regimen as first line systemic therapy in Child–Pugh class A advanced HCC patients (with Atezo-Bev and durvalumab plus tremelimumab as preferred regimen)	[8]
		Subsequent line systemic therapy if disease progression
ASCO	2020	First line treatment for Child–Pugh class A and ECOG PS 0–1 patients with advanced HCC where there are contraindications to Atezo-Bev	[9]
		Second line therapy following first line treatment with Atezo-Bev
ESMO	2021	First line systemic option in advanced HCC (while Atezo-Bev regarded as standard)	[10]
		Second line systemic option with progression after Atezo-Bev
EASL	2021	First line systemic treatment for advanced HCC with contraindication to Atezo-Bev	[11]
		Second line systemic therapy after progression of Atezo-Bev
KLCA-NCC	2022	Recommended as first line systemic therapy for Child–Pugh class A ECOG PS 0–1 patients with advanced HCC who are unsuitable for Atezo-Bev and durvalumab plus tremelimumab	[12]
		Considered as second line systemic therapy after failure with Atezo-Bev or durvalumab plus tremelimumab

Abbreviations: NCCN, National Comprehensive Cancer Network; ASCO, American Society of Clinical Oncology; ESMO, European Society for Medical Oncology; EASL, European Association for the Study of the Liver; KLCA-NCC, Korean Liver Cancer Association–National Cancer Center; HCC, hepatocellular carcinoma; Atezo-Bev, atezolizumab and bevacizumab; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

National Comprehensive Cancer Network (NCCN). NCCN guidelines: hepatocellular carcinoma [Internet]. Plymouth Meeting (US): NCCN; [cited 2023 May 1,]. Available from.: https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf.

 Google Scholar

Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38:4317–4345. doi:10.1200/JCO.20.02672

 PubMed Web of Science ®Google Scholar

Vogel A, Martinelli E; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32:801–805.

 PubMed Web of Science ®Google Scholar

Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75(960):960–974. doi:10.1016/j.jhep.2021.07.004

 PubMedGoogle Scholar

Korean Liver Cancer Association (KLCA),. National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28:583–705.

 PubMed Web of Science ®Google Scholar